REGULATORY

• More Patient Participation Needed to Promote Drug Development, Safety Measures: MHLW Official
  November 25, 2016

• Keytruda Clears MHLW Panel for Both 1st-Line, 2nd-Line NSCLC
  November 25, 2016

• Polaprezinc Ordered to Add Copper Deficiency in ADR List
  November 24, 2016

• LDP’s Health Committee Demands Enhanced R&D Tax Break as Key Priority
  November 24, 2016

• MHLW OKs Janssen’s HIV Combo Pill Prezcobix
  November 24, 2016

• AMED to Allocate 240 Million Yen for R&D of Innovative Cancer Treatments, Including CAR-T Cell Therapy
  November 24, 2016

• MHLW to Announce Opdivo’s New Prices on Nov. 24
  November 24, 2016

• MHLW to Revise Rules on Development Requests for Unapproved Drugs
  November 22, 2016

• Council OKs Public Knowledge-Based Application for Tamiflu’s New Pediatric Dosage
  November 22, 2016

• MHLW to Set Up Quake-Resistant Warehouse to Stockpile Vaccines Using Supplementary Budget for FY2016
  November 21, 2016

• MHLW to Kick Off Discussions for Major Drug Pricing Overhaul by Year-End: Bureau Chief
  November 18, 2016

• MOF Panel Budget Recommendation Calls for Curbing Drug Costs
  November 18, 2016

• 10 APIs/17 Products to Join NHI Price List on Nov. 18
  November 17, 2016

• Chuikyo Floats Reimbursement Claims Based on “Amount Used” in Lieu of “Vial Units”
  November 17, 2016

• Doctor, Industry Reps Get in Spat over Indication Additions: Chuikyo
  November 17, 2016

• 50% Price Cut for Opdivo OK’ed with Estimated Sales of 151.6-Plus Billion Yen
  November 17, 2016

• ICH Eyes Major GCP Revamp with Use of Real World Data: Osaka Confab
  November 16, 2016

• 3 Immunosuppressants to Be Discussed for Lifting of Contraindicated Pregnancy Use
  November 16, 2016

• Opdivo’s NHI Price-Based Sales Put at Over 151 Billion Yen; 50% Cut Likely to Take Effect Feb. 1
  November 15, 2016

• MHLW Advisory Committee to Review Biogen’s MS Drug on Nov. 25
  November 14, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 260
• 261
• 262
• 263
• 264
• 265
• 266
• 267
• 268
• …
• Next ›
• 最終 »